# Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation

Amadeus T. Heinz,<sup>1\*</sup> Friso G.J. Calkoen,<sup>2\*</sup> Alexander Derbich,<sup>1</sup> Lea Miltner,<sup>1</sup> Christian Seitz,<sup>1</sup> Michaela Doering,<sup>1</sup> Christiane Braun,<sup>1</sup> Daniel Atar,<sup>1</sup> Michael Schumm,<sup>1</sup> Florian Heubach,<sup>1</sup> Anne-Marie Arendt,<sup>1</sup> Ansgar Schulz,<sup>3</sup> Friedhelm R. Schuster,<sup>4</sup> Roland Meisel,<sup>4</sup> Brigitte Strahm,<sup>5</sup> Juergen Finke,<sup>6</sup> Beatrice Heineking,<sup>7</sup> Susanne Stetter,<sup>8</sup> Gerda Silling,<sup>9</sup> Daniel Stachel,<sup>10</sup> Bernd Gruhn,<sup>11</sup> Klaus-Michael Debatin,<sup>3</sup> Juergen Foell,<sup>12</sup> Johannes H. Schulte,<sup>13</sup> Wilhelm Woessmann,<sup>14</sup> Christine Mauz-Koerholz,<sup>14,15</sup> Johanna Tischer,<sup>16</sup> Tobias Feuchtinger,<sup>17</sup> Rupert Handgretinger<sup>18</sup> and Peter Lang<sup>1</sup>

<sup>1</sup>Department of Pediatric Hematology and Oncology, University Children's Hospital Tübingen, Tübingen, Germany; <sup>2</sup>Princess Máxima Center, Utrecht, the Netherlands; <sup>3</sup>Department of Pediatrics, University Medical Center Ulm, Ulm, Germany; 4Division of Pediatric Stem Cell Therapy, Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty, Heinrich-Heine-University, Dusseldorf, Germany; <sup>5</sup>Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; <sup>6</sup>Department of Hematology and Oncology, University Hospital Freiburg, Freiburg, Germany; <sup>7</sup>Department of Pediatric Cardiology and Intensive Care Medicine, Ludwig-Maximilians-University, Munich, Germany; <sup>8</sup>Department of Medicine III, University Hospital Regensburg, Regensburg, Germany; <sup>9</sup>Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, RWTH Aachen University, Aachen, Germany; <sup>10</sup>Hospital for Pediatric and Adolescent Medicine, University of Erlangen, Erlangen, Germany; 11Department of Pediatrics, Jena University Hospital, Jena, Germany; <sup>12</sup>Department of Hematology and Oncology, University Children's Hospital Regensburg, Regensburg, Germany; <sup>13</sup>Department of Pediatric Oncology & Hematology, Charité University Medicine, Berlin, Germany; <sup>14</sup>Department of Pediatric Hematology and Oncology, Justus-Liebig-University, Giessen, Germany; <sup>15</sup>Medical Faculty of the Martin-Luther-University of Halle-Wittenberg, Halle, Germany; <sup>16</sup>Department of Medicine III, Ludwig-Maximilians-University, Munich, Germany; <sup>17</sup>Department of Pediatric Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Dr. von Hauner University Children's Hospital, Munich, Germany and <sup>18</sup>Abu Dhabi Stem Cells Center, Rowdhat, Abu Dhabi, UAE

\*ATH and FGJC contributed equally as first authors.

#### **Correspondence:** Amadeus T. Heinz amadeus.heinz@med.uni-tuebingen.de

<b>Received:</b>	А
Accepted:	F
Early view:	F

August 25, 2022. February 3, 2023. February 16, 2023.

#### https://doi.org/10.3324/haematol.2022.281996

©2023 Ferrata Storti Foundation Published under a CC BY-NC license 座 0 😒 **Supplementary Figure 1**: Flow chart of diagnoses, type of stem cell donor and type of viral infection in n=25 patients with known main diagnosis (n=1 diagnosis not specified)



ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; BMF: bone marrow failure, congenital (n=1) or due to Fanconi anemia (n=1); HLH: hemophagocytic lymphohistiocytosis; MDS: myelodysplastic syndrome; PTLD: post-transplant lymphoproliferative disease; SCD: sickle cell disease; SCID: severe combined immunodeficiency

### Supplementary Table 1:

	0	1	2	3	4
Diarrhea	21	0	0	1	1
Nausea	21	1	0	1	0
Skin	22	1	0	0	0
Fever	20	0	3	0	0
Infection	22	1	0	0	0
Total		3	3	2	1

Toxicity attributed to virus specific T cell infusion graded according to CTCAE v3

CTCAE v3: Common Terminology Criteria of Adverse Events version 3

## Supplementary Table 2:

Total count of virus specific symptoms before start of treatment

Symptoms	ADV	CMV	EBV
Nausea	5	1	1
Diarrhea	5	1	
Hepatitis	2	1	
Acute kidney injury	1		
Encephalitis	1		
Pneumonia	1	6	
Dysphagia			1

ADV: adenovirus; CMV: (human) cytomegaly virus; EBV: Epstein Barr virus

## Supplementary Table 3:

Causes of death (n=18) in responding (n=20) and non-responding (n=6) patients as

described by treating physician

Prior response	Status of viral infection at	Cause of death	N
to treatment	death		
yes	Deceased due to viral infection	ADV infection	1
	Deceased with viral infection	Fungal pneumonia	1
		Multi-organ failure	1
	Prior curation of viral infection	ARDS	2
		Multi-organ failure	2
		Respiratory failure	2
	Non-infection related	Relapse of primary disease	3
Total			12/20
no	Deceased due to viral infection	ADV infection	2
		CMV pneumonia	1
	Deceased with viral infection	Cardiogenic shock	1
		Intracranial hemorrhage	1
		Multi-organ failure	1
Total			6/6